BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 28616729)

  • 1. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
    McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
    J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
    Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
    Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 10. T1 mapping in children and young adults with hypertrophic cardiomyopathy.
    Parekh K; Markl M; Deng J; de Freitas RA; Rigsby CK
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):109-117. PubMed ID: 27659477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.
    Li Y; Liu X; Yang F; Wang J; Xu Y; Fang T; Pu L; Zhou X; Han Y; Chen Y
    Eur Radiol; 2021 Jul; 31(7):4557-4567. PubMed ID: 33449190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cardiac magnetic resonance-based personalized risk stratification model in dilated cardiomyopathy: a prospective study.
    Zhou D; Zhu L; Wu W; Zhuang B; He J; Xu J; Yang W; Wang Y; Li S; Sun X; Sharma P; Liu G; Sirajuddin A; Arai A; Zhao S; Lu M
    Eur Radiol; 2024 Jun; 34(6):4053-4064. PubMed ID: 37950081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of Late Gadolinium Enhancement and Extracellular Volume Fraction to Ventricular Arrhythmias in Hypertrophic Cardiomyopathy.
    Levine J; Collins JD; Ogele E; Murtagh G; Carr JC; Bonow RO; Choudhury L
    Am J Cardiol; 2020 Sep; 131():104-108. PubMed ID: 32718552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in hypertrophic cardiomyopathy in children: An MRI based study.
    Ali LA; Marrone C; Martins DS; Khraiche D; Festa P; Martini N; Santoro G; Todiere G; Panaioli E; Bonnet D; Boddaert N; Aquaro GD; Raimondi F
    Int J Cardiol; 2022 Oct; 364():141-147. PubMed ID: 35718011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance.
    Mavrogeni S; Petrou E; Kolovou G; Theodorakis G; Iliodromitis E
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):518-25. PubMed ID: 23324829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
    Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.